Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA:688621)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Innovative Drugs and Improved New Drugs	248.36M	-	-	-	-
Clinical Trials and Bioanalytical Services	522.56M	511.65M	362.39M	234.50M	-
Pharmacy Research Services	338.48M	558.68M	568.60M	441.90M	-
Equity Sharing	10.94M	6.53M	-	-	-
Intellectual Property Licensing	100.00M	-	-	-	-
Total	1.22B	1.08B	930.98M	676.39M	-

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
China	1.22B	1.08B	932.12M	676.61M	493.65M
Total	1.22B	1.08B	932.12M	676.61M	493.65M

Data Source: S&P Global Market Intelligence Last updated: Aug 28, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 30, 2026

Data Sources Report a data error